Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs KLA Corp. (KLAC) Price & Performance

Bristol-Myers Squibb CoTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs KLA Corp. — how do they compare? Bristol-Myers Squibb Co trades at $63.61 (market cap $129.94B), while KLA Corp. trades at $207.93 (market cap $261.92B). The key difference: KLA Corp. is far larger — about 2× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.

BMYKLAC
Market Cap
$129.94B$261.92B
Sector
HealthTechnology
52-Week High
$65.89$301.71
52-Week Low
$42.60$84.39
Enterprise Value
$163.92B$263.17B
Dividend Yield
3.96%0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

KLA Corp.

KLA Corporation (KLAC) trades at $208.27, up 8.06% on the day, reflecting strong momentum amid the AI-driven semiconductor equipment rally. The stock exhibits bullish technical signals with recent earnings beats and robust profitability, including a 35.57% net income margin. Recent corporate actions include a 1:10 stock split and dividend declarations, while analyst consensus leans heavily bullish with a $246.93 price target.

Outlook remains positive given KLAC's exposure to advanced packaging growth and AI chip demand, though elevated valuation ratios (P/E of 54.77) and technical overbought conditions near resistance at $209 pose near-term risks. Long-term investors may find value in its fundamental strength, but volatility from sector cyclicality warrants caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About KLA Corp.

KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.

Read more on KLAC